secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001390478-22-000030
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS revises REGAL trial SAP; observed OS ~2-fold longer, enrollment to 125-140
--------------------------------------------------------------------------------

- Pooled blinded data shows overall survival ~2-fold longer than original protocol assumption; interim analysis reduced to 60 events, final to 80.
- Enrollment target increased from 116 to 125-140 patients; partner 3D Medicines to add ~20 patients from China.
- Milestone payments from 3DMed expected in H1 2023; potential for earlier China market entry if REGAL meets endpoints.
- Q3 2022 net loss $7.0M ($0.34 per share); cash and equivalents $21.3M as of Sep 30, 2022.
- Company hosting virtual investor event on REGAL update at 8:30 a.m. ET today.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000139047822000030/0001390478-22-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000139047822000030/sls-20221114.htm
  HTML page:      https://secwatch.observer/filing/0001390478-22-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer